West Coast Biologicals has elected Dr. Mark P. Backer as president and CEO.
Protein sensor company ECI Biotech has hired executive Anthony J. Bernardo as its CEO and president.
PDL BioPharma announced that Andrew Guggenhime will join as senior vice president and CFO effective April 3.
Replidyne has appointed Mark Smith as its CFO.
Clarient has named Jay Roberts to the position of acting CFO.
PolyMedix announced that it has appointed Edward Smith as vice president, finance and CFO.
Phase III Medical has named Larry A. May, former treasurer of Amgen, as its new CFO.
The Medicines Company announced that Glenn Sblendorio has joined the company as an executive vice president and will become CFO effective March 17.
VLST Corp. announced the appointment of Julie M. Eastland as CFO.
The Perrigo Company announced that CFO Douglas R. Schrank will retire from his post on June 30.
James A. Keller has been named CFO and Mark R. Robillard has been named vice president of sales and marketing, for Cerionx.
Advanced Bio-Surfaces hired Mark Fisher as vice president of sales.
ProEthic Pharmaceuticals has promoted William Maichle to senior vice president, product development and technical operations.
Exagen Diagnostics announced that Dr. Thomas Williams has been named chief science officer and vice president, research and development.
HistoRx announced the addition of Thomas E. Gerson as vice president of business operations and CFO.
Myriad Genetics named Jose Fojas has been appointed vice president of marketing for Myriad Pharmaceuticals.
Ernest A. Bognar has been named general manager of Dendreon Corporation's new manufacturing facility in Hanover, New Jersey.
iCo Therapeutics announced that Dr. Alan Bird has joined iCo's Strategic Advisory Team.
Endovasc announced that Robert B. Rutherford M.D., FACS, FRCS has accepted Endovasc's invitation to act as scientific advisor for the Phase III studies on Liprostin.
ImmuneRegen BioSciences announced the appointment of Kelly McQueen, MD, MPH to its Drug Development Advisory Board.
Genesis Bioventures and its business advisor, Experigen Management Company, announced that Lou Lome has joined GBI as a scientific advisor.
CytoDyn has named Dr. Trevor Hawkins to its scientific advisory board.
Ambit Biosciences named Nicholas Lydon, Ph.D., David Armistead, Ph.D., and Ed Roberts, Ph.D., to its scientific advisory board. The company also announced that Lydon and Wendell Wierenga, Ph.D., have joined Ambit's board of directors.
Vesta Therapeutics announced the establishment of a scientific advisory board assembled to assist in the clinical development of a promising new approach to treat patients with various liver diseases. Board members include Dr. Sanjeev Gupta, Dr. Mark Kay, Dr. Eric Lagasse and Dr. Lola Reid.
Encysive Pharmaceuticals today announced that Frank C. Carlucci will not stand for re-election and plans to retire from the company's board.